Last CNY9.69 CNY
Change Today 0.00 / 0.00%
Volume 0.0
600351 On Other Exchanges
As of 2:05 AM 02/3/15 All times are local (Market data is delayed by at least 15 minutes).

yabao pharmaceutical group-a (600351) Snapshot

Previous Close
Day High
Day Low
52 Week High
10/16/14 - CNY11.08
52 Week Low
03/31/14 - CNY7.28
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for YABAO PHARMACEUTICAL GROUP-A (600351)

Related News

No related news articles were found.

yabao pharmaceutical group-a (600351) Related Businessweek News

No Related Businessweek News Found

yabao pharmaceutical group-a (600351) Details

Yabao Pharmaceutical Group Co., Ltd, a specialty pharmaceutical company, is engaged in the research and development, manufacture, and operation of western and Chinese medicines, APIs, health care products, and packing materials for medicines in China and internationally. The company’s marketed products are in cardiovascular, oncology, pediatric, and women’s health areas; and research and development programs in diabetes, inflammation, and cerebrovascular areas. It also provides finished drug products in various forms, such as tablets, injections, capsules, granules, and suppositories, as well as in powders for injections; and TCM products. In addition, the company is involved in planting and processing medicinal herbs; and producing packing material for medicine, such as plastic bottles, adhesive labels, bottles cushions, carton boxes, cartons etc. Yabao Pharmaceutical Group Co., Ltd was founded in 1978 and is based in Yuncheng, China.

Founded in 1978

yabao pharmaceutical group-a (600351) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

yabao pharmaceutical group-a (600351) Key Developments

Yabao Pharmaceutical Group Co., Ltd(SHSE:600351) added to Shanghai Stock Exchange Health Care Sector Index

Yabao Pharmaceutical Group Co., Ltd will be added to the Shanghai Stock Exchange Health Care Sector Index.

Yabao Pharmaceuticals Partners with MRC Technology

MRC Technology and Yabao Pharmaceuticals Group Co. Ltd. have announced a license agreement to discover, develop and commercialize compounds targeting a specific kinase involved in neurodegeneration, with the aim of developing novel therapeutics for the treatment of Parkinson's disease. Under the terms of the agreement, Yabao receives exclusive rights to discover, develop and commercialize the therapeutics in China, Taiwan and Hong Kong, while MRC retains rights in all other markets.

Yabao Pharmaceutical Group Co., Ltd Announces Earnings Results for the Nine Months of 2014

Yabao Pharmaceutical Group Co. Ltd. announced earnings results for the nine months of 2014. For the period, the company reported basic earnings per share of CNY 0.20 and weighted average return on net assets of 8.06%.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
600351:CH CNY9.69 CNY 0.00

600351 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 600351.
View Industry Companies

Industry Analysis


Industry Average

Valuation 600351 Industry Range
Price/Earnings 42.9x
Price/Sales 3.4x
Price/Book 3.5x
Price/Cash Flow 43.2x
TEV/Sales 2.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact YABAO PHARMACEUTICAL GROUP-A, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at